Accelerated IBC Review Core offering is accelerated, compliant site-specific Institutional Biosafety Committee review for gene therapy trials. This creates sales opportunities with biotech sponsors and academic institutions seeking fast activation. Propose scalable engagement models such as ongoing retainer support and remote review collaboration to shorten cycle times.

Regulatory Burden Reduction Its focus on reducing regulatory burden and uncertainty during IBC reviews opens cross-selling avenues into related biosafety and regulatory services, including risk assessments, SOP development, training programs, and IND enabling guidance for broader client wallets.

Target Institutions The service is positioned for institutions and sponsors involved in gene transfer/gene therapy, offering site-specific review and a bridge between sponsor needs and institutional processes. Potential to lock in multi-trial, multi-year engagements through programmatic IBC readiness and audits, expanding customer lifetime value.

Sabai Global Synergy As a Sabai Global subsidiary, there are opportunities to co-sell with other group entities and tap into a broader biotech network, enabling larger deals and integrated regulatory solutions through cross-pollination and partner referrals.

Gene Therapy Growth Growth in the gene therapy market drives demand for specialized regulatory review and biosafety consulting; target emerging startups, CROs, and academic centers launching first-in-human trials to capture early mover advantages and expand the client base in a high-growth segment.